Here are relevant reports on : oral-drug-delivery-market
-
Gold Nanoparticles Market by Process (Physical, Chemical, Biological), Application (Imaging, Targeted Drug Delivery, Proton Therapy, In-Vitro Assays, Sensors, Probes, Catalysis), End-Use Industry and Region - Global Forecast to 2029
The gold nanoparticles market is expected to grow from USD 0.50 billion in 2024 to USD 1.11 billion in 2029, at a CAGR of 16.3% during the forecast period. Prominent companies include BBI Solutions (UK), Cytodiagnostics Inc (Canada), Fortis Life Sciences, LLC. (US), Meliorum Technologies, Inc (US), TANAKA PRECIOUS METAL GROUP Co., Ltd. (Japan), Merck KGaA (Germany), Nanopartz, Inc (US), CD Bioparticles (US), Nano Labs (India), Nanocs Inc. (US), NanoHybrids (US), Sona Nanotech (Canada), Sisco Research Laboratories Pvt, Ltd. (India), Nanoprobes, Inc (US), American Elements (US), TORSKAL (France), Abcam Limited (UK), Particular GmbH (Germany), Dongguan Sat Nano Technology Material Co., Ltd (China), Nano Flow (Belgium), Strem Catalog (US), Nanorh (India), SkySpring Nanomaterials (US), Aurion (Netherlands), NNCrystal US Corporation (US), and among others.
- Published: March 2025
- Price: $ 4950
- TOC Available:
-
Live Cell Encapsulation Market by Technique (Dripping (Simple, Electrostatic), Coaxial Airflow, Liquid Jet), Polymer (Alginate, Chitosan, Silica, Cellulose Sulfate), Application (Probiotics, Transplant, Drug Delivery, Research) - Forecast to 2024
The live cell encapsulation market is projected to grow to USD 303 million by 2024 from USD 250 million in 2018, at a CAGR of 3.2% during the forecast period. Growth in the live cell encapsulation market is primarily driven by factors such as the increasing public-private investments to support product development, increasing research to establish the clinical efficacy of cell encapsulation technologies, and rising public awareness related to the clinical role of encapsulated cells in disease management. BioTime, Inc. (US), Viacyte, Inc. (US), and Living Cell Technologies Ltd. (Australia) were the top three players in the live cell encapsulation market. Other prominent players operating in this market include Sigilon Therapeutics, Inc. (US), Evonik Industries (Germany), BÜCHI Labortechnik AG (Germany), Blacktrace Holdings Ltd (UK), and Sernova Corporation (Canada), among others. Furthermore, the key players in the developmental pipeline products in this market include Neurotech Pharmaceuticals, Inc. (US), Gloriana Therapeutics (US), Kadimastem (Israel), Beta-O2 Technologies, Inc. (Israel), Defymed (France), and Altucell, Inc. (US), among others.
- Published: April 2019
- Price: $ 4950
- TOC Available:
-
Bioresorbable Polymers Market by Type (Polylactic Acid (PLA), Polyglycolic Acid (PGA), Polylactic-co-glycolic acid (PLGA), Polycaprolactone) PCL), Application (Orthopedic Devices, Drug Delivery), and Region - Global Forecast to 2029
The bioresorbable polymers market is expected to grow from USD 500.0 million in 2024 to USD 867.2 million by 2029, at a CAGR of 11.6% during the forecast period. The key players profiled in the report include Corbion (Netherlands), Evonik Industries AG (Germany), Foster Corporation (US), KLS Martin Group (Germany), DSM Biomedical (US), Ashland Global Holdings Inc. (US), Zeus Company LLC (US), Seqens (France), Reva Medical, LLC (US), and Poly-Med Incorporated (US).
- Published: November 2024
- Price: $ 4950
- TOC Available:
-
Europe Injectable Drug Delivery Market by Product (Device, Self Injection, Formulation, Solution, Emulsions), Formulation Packaging (Ampoules, Bottles), Therapeutic Application (Obesity, Diabetes, Cancer, Psoriasis), Usage Pattern - Forecast to 2031
The Europe injectable drug delivery market, valued at US$166.13 billion in 2025, stood at US$178.87 billion in 2026 and is projected to advance at a resilient CAGR of 7.7% from 2026 to 2031, culminating in a forecasted valuation of US$259.49 billion by the end of the period. The increasing use of biologics, biosimilars, and long-acting injectables is driving market growth. There is an increasing demand for patient-centric delivery systems and self-administration in major healthcare markets.
- Published: April 2026
- Price: $ 4950
- TOC Available:
-
Asia Pacific Injectable Drug Delivery Market by Product (Device, Autoinjectors, Formulation, Suspensions, Nanoparticles), Site of Administration (Dermal, Organ), Formulation Packaging (Ampoules, Vials), Usage Pattern (Curative, Immunization) - Forecast to 2031
The Asia Pacific injectable drug delivery market, valued at US$161.32 billion in 2025, stood at US$176.96 billion in 2026 and is projected to advance at a resilient CAGR of 9.8% from 2026 to 2031, culminating in a forecasted valuation of US$282.22 billion by the end of the period. The growth of the Asia Pacific injectable drug delivery market is driven by the increasing incorporation of biologics, biosimilars, and long-acting injectables, alongside a rapidly growing patient population and an escalating burden of chronic diseases across major countries in the region.
- Published: April 2026
- Price: $ 4950
- TOC Available:
-
Europe Medical Tubing Market by Material (Plastics, Rubber, Specialty Polymers), Application (Bulk Disposable Tubing, Catheters & Cannulas, Drug Delivery Systems), Structure (Single Lumen, Multi Lumen, Co-Extruded, Braided), and Country - Forecast to 2030
The Europe medical tubing market is projected to grow from USD 3.64 billion in 2025 to USD 5.14 billion by 2030, at a CAGR of 7.1% during the forecast period. The key global players in the Europe medical tubing market are Freudenberg Medical (US), RAUMEDIC AG (Germany), Vygon (France), B. Braun (Germany), Saint-Gobain (France), Trelleborg Medical (Sweden), Teleflex (US), Coloplast (Denmark), Smiths Medical (US), and TE Connectivity (Ireland).
- Published: April 2026
- Price: $ 4950
- TOC Available:
-
Oral Rinses Market by Product Type (Therapeutic, Cosmetic, Other Rinses), Indication (General Oral Health, Gingivitis & Periodontal Diseases), Distribution Channel (Consumer Stores, Retail Pharmacies, Dental Dispensaries), Region - Global Forecast to 2030
The global oral rinses market, valued at US$4.09 billion in 2024, stood at US$4.30 billion in 2025 and is projected to advance at a resilient CAGR of 6.5% from 2025 to 2030, culminating in a forecasted valuation of US$5.89 billion by the end of the period. With extensive benefits for dentists and consumers, oral rinses rapidly transform modern oral hygiene routines.
- Published: July 2025
- Price: $ 4950
- TOC Available:
-
Biopharmaceutical Contract Manufacturing Market by Service (Manufacturing, Fill-Finish), Type (Drug Substance, Drug Product), Scale (Clinical), Source (Mammalian), Therapy Area (Oncology), Molecule Type (mAbs, ADC, CGT, Vaccines) - Global Forecast to 2030
The global biopharmaceutical contract manufacturing market, valued at US$20.51 billion in 2024, stood at US$22.40 billion in 2025 and is projected to advance at a resilient CAGR of 8.8% from 2025 to 2030, culminating in a forecasted valuation of US$34.15 billion by the end of the period. The growth is primarily driven by the rising demand for outsourcing services and an increasing need for biologics and biosimilars. However, challenges related to intellectual property rights are anticipated to pose barriers to market growth.
- Published: July 2025
- Price: $ 4950
- TOC Available:
-
Therapeutic Drug Monitoring Market by Product (Equipments,Consumables), Technology (Immunoassays), Drug Class (AntiEpileptic Drugs,AntiArrhythmic Drugs), Therapeutic Area (Oncology, Cardiology), Specimen (Blood), End user - Global Forecast to 2029
The global therapeutic drug monitoring market, valued at US$2.14 billion in 2023, stood at US$2.30 billion in 2024 and is projected to advance at a resilient CAGR of 8.4% from 2024 to 2029, culminating in a forecasted valuation of US$3.44 billion by the end of the period. This growth is brought on by a number of causes, such as the rise in chronic diseases like cancer, heart disease, epilepsy, and autoimmune conditions.
- Published: December 2024
- Price: $ 4950
- TOC Available:
-
Specimen Validity Testing Market by Product (Reagent, Controls, Assay Kits, Disposables), Type (Laboratory, POC Testing), End User (Workplace, Drug Screening, Pain Management, Drug Rehabilitation Centers) - Global Forecast to 2023
The global specimen validity testing market is projected to reach USD 1.49 Billion by 2023 from USD 1.10 Billion in 2018, at a CAGR of 6.3%. The growth of the market is primarily driven by the growth in drug screening market and increase in workplace drug testing. While the specimen validity testing market represents significant growth opportunities, market growth may be hindered due to the emergence of alternative drug screening tests. The specimen validity testing market is marked by the presence of several big and small players. Prominent players offering specimen validity testing products include Thermo Fisher Scientific (US), Sciteck, Inc. (US), American Bio Medica Corporation (ABMC), Alere [now a part of Abbott (US)], Express Diagnostics Int'l, Inc. (US), and Premier Biotech, Inc. (US). While, Laboratory Corporation of America Holdings (LabCorp) (US), Quest Diagnostics (US), Alere Toxicology (Alere) (US), ACM Global Laboratories (US), Clinical Reference Laboratory (CRL) (US), SureHire (Canada), and CannAmm (Canada) are some of the leading service providers.
- Published: May 2018
- Price: $ 4950
- TOC Available:
Records 41 to 50 of 50
